Therapeutic approaches to bone diseases
- PMID: 10968781
- DOI: 10.1126/science.289.5484.1508
Therapeutic approaches to bone diseases
Abstract
The strength and integrity of our bones depends on maintaining a delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts. As we age or as a result of disease, this delicate balancing act becomes tipped in favor of osteoclasts so that bone resorption exceeds bone formation, rendering bones brittle and prone to fracture. A better understanding of the biology of osteoclasts and osteoblasts is providing opportunities for developing therapeutics to treat diseases of bone. Drugs that inhibit the formation or activity of osteoclasts are valuable for treating osteoporosis, Paget's disease, and inflammation of bone associated with rheumatoid arthritis or periodontal disease. Far less attention has been paid to promoting bone formation with, for example, growth factors or hormones, an approach that would be a valuable adjunct therapy for patients receiving inhibitors of bone resorption.
Similar articles
-
Clinical disorders of bone resorption.Novartis Found Symp. 2001;232:251-67; discussion 267-71. doi: 10.1002/0470846658.ch17. Novartis Found Symp. 2001. PMID: 11277085 Review.
-
Is prolonged stimulation of bone growth a therapeutic possibility?Mol Cell Endocrinol. 1991 Feb;75(2):C19-25. doi: 10.1016/0303-7207(91)90222-e. Mol Cell Endocrinol. 1991. PMID: 2050268 Review. No abstract available.
-
Osteoporosis into the year 2010.Br J Obstet Gynaecol. 1996 May;103 Suppl 13:32-7; discussion 37-8. Br J Obstet Gynaecol. 1996. PMID: 8624340 Review. No abstract available.
-
Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.J Cell Biochem. 2011 May;112(5):1229-42. doi: 10.1002/jcb.23049. J Cell Biochem. 2011. PMID: 21465521
-
Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis.Trends Pharmacol Sci. 1995 Nov;16(11):382-6. doi: 10.1016/s0165-6147(00)89079-3. Trends Pharmacol Sci. 1995. PMID: 8578607 Review.
Cited by
-
Inhibitory Effects of Protopanaxadiol-Producing Transgenic Rice Seed Extracts on RANKL-Induced Osteoclast Differentiation.Life (Basel). 2022 Nov 14;12(11):1886. doi: 10.3390/life12111886. Life (Basel). 2022. PMID: 36431021 Free PMC article.
-
Drug Delivery to the Bone Microenvironment Mediated by Exosomes: An Axiom or Enigma.Int J Nanomedicine. 2021 May 21;16:3509-3540. doi: 10.2147/IJN.S307843. eCollection 2021. Int J Nanomedicine. 2021. PMID: 34045855 Free PMC article. Review.
-
Schisandrin B Inhibits Osteoclastogenesis and Protects Against Ovariectomy-Induced Bone Loss.Front Pharmacol. 2020 Jul 31;11:1175. doi: 10.3389/fphar.2020.01175. eCollection 2020. Front Pharmacol. 2020. PMID: 32848781 Free PMC article.
-
Bone scaffolds loaded with siRNA-Semaphorin4d for the treatment of osteoporosis related bone defects.Sci Rep. 2016 Jun 2;6:26925. doi: 10.1038/srep26925. Sci Rep. 2016. PMID: 27254469 Free PMC article.
-
NF-κB signaling and bone resorption.Osteoporos Int. 2013 Sep;24(9):2377-86. doi: 10.1007/s00198-013-2313-x. Epub 2013 Mar 7. Osteoporos Int. 2013. PMID: 23468073 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
